Research progress of primary testicular lymphoma and primary central nervous system lymphoma: reports from the 19th European Hematology Association annual congress / 白血病·淋巴瘤

Primary testicular lymphoma (PTL) is an uncommon extranodal lymphoma,with an aggressive clinical course and poor outcome.A combined treatment with full-course anthracycline-based chemotherapy with rituximab and central nervous system prophylaxis with intrathechal methotrexate and contralateral testicular radiotherapy should be considered as the standard of care at limited stage.These patients have a very high risk of central nervous system recurrence and the addition of systemic central nervous system prophylaxis with intravenous methotrexate may be the best treatment option.Primary central nervous system lymphoma (PCNSL) is an aggressive disease with a dismal prognosis,particularly when treated with established protocols used for systemic non-Hodgkin lymphoma.Use of methotrexate in combination with cytarabine has been proposed as a standard induction regimen.The role of the anti-CD20 antibody has not yet been defined,however,phase Ⅰ and Ⅱ trials suggest its efficacy despite low penetration within the cerebrospinal fluid.High-dose chemotherapy followed by autologous stem cell transplantation has shown high remission rates with 3-year overall suvival rates of up to 87 ％.

Current diagnosis and treatment progress of primary myelofibrosis: reports from the 19th European Hematology Association annual congress / 白血病·淋巴瘤

Primary myelofibrosis is a kind of chronic myeloproliferative neoplasms.The discovery of the JAK2V617F mutation as well as other molecular abnormlities underly the pathogenesis of Philadelphia negative myeloproliferative neoplasms (MPN).The initial description of JAK2V617F mutation in 2005,the reporting of calreticulin (CALR) mutations last year and the clinical application of JAK inhibitors,showed the gradually deepening understanding with regard to the pathogenesis and the development of therapeutic strategies for primary myelofibrosis (PMF).This article reviewed the progress in diagnosis,risk stratification of of PMF,the benefits and potential side effect of JAK inhibitors,which reported on the 2014 European Hematology Association annual congress.

Research progress of aggressive B-cell lymphoma: reports from the 19th European Hematology Association annual congress / 白血病·淋巴瘤

Aggressive B-cell lymphoma is characterized by malignant behaviour and rapid progression.Patients are prone to drug resistance or relapse of disease.The 19th European Hematology Association (EHA)annual congress explored several aspects about aggressive B-cell lymphoma.PET-CT examination provided new tools for the indication of prognosis.The elevated dose of rituximab improved the outcome of elderly male patients.Novel drugs or methods including bortezomib,ABT-199,combined targeted therapy and CNS prophylaxis have shown encouraging results in various clinical trials which provide new hope for patients with aggressive B-cell lymphoma.

Perspectives on the diagnosis and treatment of the relapsed/refractory multiple myeloma: highlight of the 19th European Hematology Association annual congress / 白血病·淋巴瘤

Relapsed/refractory multiple myeloma (MM) is always a challenge in the field of MM treatment.In the 19th European Hematology Association (EHA) annual congress,there was a detailed and full-length description on the definition,prognosis,therapeutic strategies and new drugs of the relapsed/refractory MM.New agents with activity and good tolerability are promising in the future.

Recent progress of acute lymphoblastic leukemia: reports from the 19th European Hematology Association annual congress / 白血病·淋巴瘤

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease affected by many factors,including age,immunologic subtype,and clinical,genetic and molecular features,Improved tools can identify patients in remission based on morphology but those with active disease based on molecular biology or immunophenotype (minimal residual disease).B-cell antigen panels,clone-specific immunoglobulins,or T-cell receptor rearrangements is used to detect positivity at thresholds at least.There are 13 ALL clinical related abstracts (poster) in the 19th European Hematology Association annual congress which reflected recent progress of research ALL.

Current treatment and blueprint of CD30+ T-cell lymphomas: reports from the 19th European Hematology Association annual congress / 白血病·淋巴瘤

There is still no agreed standard of care for CD30+ T-cell lymphomas which are dominant in peripheral T-cell lymphoma.The combination of multidrug or dose-intensified chemotherapy regimen and consolidation of hematopoietic stem cell transplantation are widely used at present.In recent years,several clinical trails included certain new agents,such as etoposide,alemtuzumab,denileukin diftitox,bortezomib,romidepsin,lenalidomide,brentuximab vedotin,and so on,have demonstrated the promising outcome.Referring targeted therapies for relapsed/refractory CD30 + T-cell lymphomas,certain agents have been approved,such as pralatrexate,romidepsin,brentuximab vedotin (ALCL),belinostat,and the most encouraging agent is brentuximab vedotin.